Ferroportin (SLC40A1): Understanding a Key Iron Regulator

Ferroportin (also known as SLC40A1, FPN1, or IREG1) is not a routine clinical blood test but rather a protein—the only known cellular exporter of elemental iron in humans . Understanding ferroportin is essential for interpreting iron studies (serum iron, ferritin, transferrin saturation) and diagnosing disorders of iron overload or deficiency.

Ferroportin is a transmembrane protein expressed on the surface of cells that export iron into the bloodstream . Its primary locations include:

· Duodenal enterocytes: Exports dietary iron absorbed from food into the circulation.

· Macrophages: Releases iron recycled from senescent red blood cells (splenic and hepatic macrophages).

· Hepatocytes: Mobilises stored iron when body demands increase.

· Placental syncytiotrophoblast: Transports iron from mother to fetus.

· Erythrocytes: Present on mature red blood cells, where it may protect against iron-induced oxidative damage .

The hepcidin-ferroportin axis is the master regulator of systemic iron homeostasis. Hepcidin, a liver-derived hormone, binds to ferroportin, causing its internalisation and degradation . When hepcidin is high, ferroportin is removed from cell surfaces, trapping iron within cells and lowering serum iron. When hepcidin is low, ferroportin exports iron, raising serum iron levels.

Clinical relevance: Ferroportin function—or dysfunction—underlies several important conditions:

· Ferroportin disease (Type IV haemochromatosis): Caused by mutations in the SLC40A1 gene. Two phenotypes exist:

· Loss-of-function mutations: Iron accumulates in macrophages, with high ferritin but normal transferrin saturation.

· Gain-of-function (hepcidin-resistant) mutations: Systemic iron overload resembling HFE haemochromatosis.

· Anaemia of inflammation: Inflammatory cytokines increase hepcidin, downregulating ferroportin and trapping iron in macrophages, leading to iron-restricted erythropoiesis.

· Iron-refractory iron deficiency anaemia (IRIDA): Caused by mutations in TMPRSS6 (matriptase-2), leading to inappropriately high hepcidin and low ferroportin activity.

While ferroportin itself is not routinely measured in clinical laboratories, its function is inferred from iron studies (serum iron, TIBC, transferrin saturation, ferritin) and, in specialised centres, by genetic testing for SLC40A1 mutations.

---

2. What is measured to assess ferroportin function

a. Indirect markers of ferroportin activity

Since ferroportin is not a standard blood test, clinicians assess its function through:

Marker Relationship to Ferroportin

Serum iron Reflects iron exported by ferroportin from enterocytes, macrophages, and hepatocytes. Low ferroportin activity → low serum iron.

Transferrin saturation (TSAT) Calculated as (serum iron ÷ TIBC) × 100%. Low TSAT suggests impaired iron export (e.g., inflammation, hepcidin excess).

Serum ferritin Reflects iron stores but also acute-phase response. In ferroportin disease, ferritin may be disproportionately elevated relative to TSAT.

Hepcidin Measured in research settings; high hepcidin implies low ferroportin activity.

SLC40A1 genetic testing Identifies mutations causing ferroportin disease (Type IV haemochromatosis).

b. Normal range (genetic testing)

· Negative: No pathogenic SLC40A1 mutation detected.

· Positive: Presence of a mutation associated with ferroportin disease (autosomal dominant inheritance) .

c. Interpretation notes

· Ferroportin disease typically presents with:

· Early stage: Elevated serum ferritin, normal transferrin saturation, iron accumulation in macrophages (Kupffer cells, splenic macrophages).

· Late stage: Some patients develop elevated transferrin saturation and hepatocellular iron loading, mimicking HFE haemochromatosis.

· The Q248H mutation, common in African populations (up to 10–14% heterozygosity), is associated with:

· Mildly lower haemoglobin.

· Possible protection against anaemia and iron deficiency.

· No clear protection against malaria or bacterial infection despite earlier hypotheses .

---

3. Other factors connected to ferroportin

a. Factors that decrease ferroportin expression/activity

· High hepcidin: Inflammation (IL-6), iron overload, chronic kidney disease.

· Genetic loss-of-function mutations: SLC40A1 mutations impairing iron export (e.g., A77D, V162del) .

· Hypoxia: May increase ferroportin via HIF-2α in enterocytes, but systemic effects are complex .

b. Factors that increase ferroportin expression/activity

· Low hepcidin: Iron deficiency, hypoxia, erythropoietic drive (erythroferrone suppresses hepcidin).

· Genetic gain-of-function mutations: Hepcidin-resistant ferroportin (e.g., C326Y) .

· Heme and iron loading in macrophages: Upregulate ferroportin transcription via Nrf2 .

· Nitric oxide: Enhances ferroportin expression via Nrf2 .

c. Substrate specificity

Ferroportin preferentially exports ferrous iron (Fe²⁺), but studies in Xenopus oocytes show it can also transport cobalt (Co²⁺) and zinc (Zn²⁺), albeit with lower affinity . It does not transport copper, cadmium, or manganese under physiological conditions. However, hepcidin administration in mice lowers serum iron but not serum zinc, suggesting ferroportin's role in zinc homeostasis is minimal in vivo .

d. Post-translational regulation

Hepcidin binding induces ferroportin phosphorylation, ubiquitination, endocytosis, and lysosomal degradation . This requires an intact microtubule network .

---

4. Disorders related to abnormal ferroportin function

a. Ferroportin disease (Type IV haemochromatosis)

· Inheritance: Autosomal dominant .

· Mechanism: Missense mutations in SLC40A1.

· Phenotypes :

· Type A (loss-of-function): Impaired iron export, iron retention in macrophages, high ferritin, normal/low transferrin saturation, mild anaemia, sensitivity to phlebotomy.

· Type B (gain-of-function): Hepcidin resistance, systemic iron overload, high transferrin saturation, parenchymal iron loading (hepatocytes, pancreas), resembles HFE haemochromatosis.

b. Anaemia of inflammation (chronic disease)

· Mechanism: Inflammatory cytokines (IL-6) increase hepcidin, downregulating ferroportin.

· Consequence: Iron trapped in macrophages and enterocytes, low serum iron, iron-restricted erythropoiesis, anaemia.

c. Iron-refractory iron deficiency anaemia (IRIDA)

· Mechanism: TMPRSS6 mutations impair matriptase-2, leading to inappropriately high hepcidin.

· Consequence: Low ferroportin activity, poor dietary iron absorption, microcytic anaemia unresponsive to oral iron.

d. Q248H polymorphism

· Population frequency: ~5–14% in African and African-American populations; absent in Caucasians.

· Functional effect: Partial hepcidin resistance; 60% decrease in intracellular iron in erythroid cells.

· Clinical associations:

· Modest protection against anaemia, haemolysis, and iron deficiency .

· No significant protection against severe malaria or bacteremia in large African paediatric cohorts (OR 0.91, 95% CI 0.81–1.01 for severe malaria) .

· Trend toward higher ferritin:AST ratio and lower haemoglobin in heterozygotes .

---

5. Best way to address aberrant ferroportin function

Important principle: Ferroportin function is inferred from iron studies and genetic testing. Treatment targets the clinical phenotype, not the protein itself.

a. For ferroportin disease (Type IV haemochromatosis)

· Phenotype A (loss-of-function, macrophage iron loading):

· Phlebotomy: May not be well tolerated (risk of anaemia). Use cautiously, guided by ferritin and haemoglobin.

· Erythrocytapheresis: Alternative if phlebotomy poorly tolerated.

· Iron chelation: Deferasirox or deferoxamine if phlebotomy contraindicated.

· Avoid: Unnecessary iron supplementation.

· Phenotype B (gain-of-function, hepcidin resistance, parenchymal loading):

· Phlebotomy: Standard treatment, as for HFE haemochromatosis. Target ferritin <50–100 μg/L.

· Maintenance: Individualised based on iron studies.

b. For anaemia of inflammation

· Treat underlying inflammatory condition.

· IV iron: May be required to bypass ferroportin blockade (oral iron poorly absorbed).

· Erythropoiesis-stimulating agents (ESA): In selected cases (CKD, cancer chemotherapy).

· Emerging therapies: Hepcidin antagonists, anti-IL-6 antibodies (tocilizumab) in research settings.

c. For IRIDA

· IV iron: First-line; oral iron is ineffective.

· ESA: May be added in selected cases.

d. Dietary considerations

· Iron-rich plant foods (hierarchy adhered):

· Legumes (lentils, chickpeas, beans), tofu, tempeh, pumpkin seeds, quinoa, fortified cereals, dark leafy greens (cooked).

· Enhance absorption with vitamin C (citrus, bell peppers, amla).

· Avoid tea/coffee with meals (tannins inhibit iron absorption).

· In iron overload:

· Avoid iron-fortified foods.

· Limit high-iron plant foods only if overload is severe; phlebotomy is primary treatment.

· Avoid vitamin C supplements with meals (may enhance iron absorption).

· Tea with meals: Tannins inhibit iron absorption; can be beneficial in overload.

· Avoid: Unnecessary iron supplements, alcohol (exacerbates iron-related liver injury).

e. Supplements

· Methylfolate (5-MTHF): If anaemia present and folate deficiency documented. Avoid synthetic folic acid.

· Methylcobalamin: If B12 deficiency documented.

· Vitamin D (D3 from lichen): Support overall health; no direct effect on ferroportin.

· Curcumin (phytosomal): Anti-inflammatory; may reduce hepcidin in inflammation (limited evidence).

· Avoid: High-dose vitamin C in iron overload (can increase iron absorption and oxidative stress).

· Avoid: Unregulated herbal blends; hepatotoxicity risk.

---

6. How soon can one expect improvement and the ideal time frame to retest

For phlebotomy in ferroportin disease:

· Ferritin: Declines gradually over weeks to months depending on frequency.

· Haemoglobin: Monitor before each phlebotomy; hold if Hb drops significantly.

· Retesting: Ferritin every 1–3 months during induction; every 3–6 months in maintenance.

For IV iron in anaemia of inflammation:

· Haemoglobin: Rises over 2–4 weeks.

· Ferritin: Follow local protocols; recheck when clinically indicated.

For SLC40A1 genetic testing:

· Performed once in a lifetime. No repeat testing indicated.

---

Conclusion

Ferroportin is the sole gateway through which iron exits cells to enter the bloodstream. Its regulation by hepcidin ensures that iron flows to where it is needed—the bone marrow for erythropoiesis—while restricting iron to pathogens and preventing toxicity.

Disorders of ferroportin—whether genetic (ferroportin disease) or acquired (inflammation)—manifest as iron overload or iron-restricted anaemia. Diagnosis requires integrating iron studies, clinical context, and, when indicated, genetic testing.

A plant-based, ecologically responsible diet can support healthy iron status by providing adequate iron from legumes, greens, and fortified foods, with vitamin C to enhance absorption when needed. In iron overload, phlebotomy is the cornerstone; dietary restriction is adjunctive. Supplements—methylfolate, methylcobalamin—are used only when deficiencies coexist.

Ferroportin is not a number on a lab report, but its function shapes nearly every iron-related test clinicians order. Understanding it illuminates the elegant feedback loop that keeps our bodies in iron balance.

---x-x-

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

Special notes on iron and ferroportin:

· Iron absorption: Plant-based iron is well absorbed when paired with vitamin C and when tea/coffee are consumed between meals.

· Iron overload: Phlebotomy is primary treatment. Dietary iron restriction is secondary; avoid iron-fortified foods and vitamin C supplements with meals.

· Tea: Tannins inhibit iron absorption; can be used strategically in overload.

· Supplements: Avoid unnecessary iron; use methylfolate and methylcobalamin if folate/B12 deficiencies coexist. Avoid high-dose vitamin C in iron overload.

-x-x-